{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:40:00Z","timestamp":1779212400698,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.yebeh.2024.109784","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T02:50:50Z","timestamp":1713322250000},"page":"109784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparative analysis of adverse drug reactions associated with new antiseizure medications from the Korea Adverse Event Reporting System database"],"prefix":"10.1016","volume":"154","author":[{"given":"Hyun Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Sik","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109784_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eplepsyres.2017.10.008","article-title":"Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam","volume":"138","author":"Toledo","year":"2017","journal-title":"Epilepsy Res."},{"issue":"9","key":"10.1016\/j.yebeh.2024.109784_b0010","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.yebeh.2024.109784_b0015","first-page":"500","article-title":"Update on Antiseizure Medications 2022","volume":"28","author":"Abou-Khalil","year":"2022","journal-title":"Continuum (Minneap Minn)."},{"issue":"4","key":"10.1016\/j.yebeh.2024.109784_b0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther Adv Drug Saf."},{"key":"10.1016\/j.yebeh.2024.109784_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108666","article-title":"Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020","volume":"130","author":"Hochbaum","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.yebeh.2024.109784_b0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3988\/jcn.2022.18.2.179","article-title":"Trends in prescribing of antiseizure medications in South Korea: real-world evidence for treated patients with epilepsy","volume":"18","author":"Kang","year":"2022","journal-title":"J Clin Neurol."},{"issue":"2","key":"10.1016\/j.yebeh.2024.109784_b0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.13098","article-title":"The value of patient reporting to the pharmacovigilance system: a systematic review","volume":"83","author":"Inacio","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.yebeh.2024.109784_b0040","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf."},{"key":"10.1016\/j.yebeh.2024.109784_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107832","article-title":"Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)","volume":"117","author":"Kamitaki","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.yebeh.2024.109784_b0050","unstructured":"Safety of medicines: a guide to detecting and reporting adverse drug reactions : why health professionals need to take action. World Health Organization. 2002 [Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/67378."},{"issue":"12","key":"10.1016\/j.yebeh.2024.109784_b0055","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/pds.2244","article-title":"Pharmacovigilance systems and databases in Korea, Japan, and Taiwan","volume":"20","author":"Kimura","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"10.1016\/j.yebeh.2024.109784_b0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3715","article-title":"New initiatives for pharmacovigilance in South Korea: introducing the Korea Institute of Drug Safety and Risk Management (KIDS)","volume":"23","author":"Shin","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"10.1016\/j.yebeh.2024.109784_b0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-019-0285-y","article-title":"Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015","volume":"20","author":"Du","year":"2019","journal-title":"BMC Pharmacol Toxicol."},{"key":"10.1016\/j.yebeh.2024.109784_b0070","unstructured":"MedDRA: Introductory Guide MedDRA Version 26.0 2023 [Available from: https:\/\/www.meddra.org\/training\/schedule\/1455\/What's-New-with-MedDRA-V26.1-and-the-MSSO."},{"issue":"5","key":"10.1016\/j.yebeh.2024.109784_b0075","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol."},{"issue":"9237","key":"10.1016\/j.yebeh.2024.109784_b0080","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.yebeh.2024.109784_b0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"10.1016\/j.yebeh.2024.109784_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-016-0406-8","article-title":"Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a Clinician's overview","volume":"31","author":"Brodie","year":"2017","journal-title":"CNS Drugs."},{"issue":"8","key":"10.1016\/j.yebeh.2024.109784_b0095","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00228-019-02678-1","article-title":"Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation","volume":"75","author":"Baftiu","year":"2019","journal-title":"Eur J Clin Pharmacol."},{"issue":"Suppl 7","key":"10.1016\/j.yebeh.2024.109784_b0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","article-title":"Why are antiepileptic drugs used for nonepileptic conditions?","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia."},{"key":"10.1016\/j.yebeh.2024.109784_b0105","unstructured":"Okazaki E. CHAPTER 55 LEVETIRACETAM AND BRIVARACETAM. 7th edition ed. Wyllie E, editor: Wolters Kluwer; 20658-61 p."},{"issue":"3","key":"10.1016\/j.yebeh.2024.109784_b0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/17425255.2023.2203859","article-title":"Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase","volume":"19","author":"Petrovic","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"10.1016\/j.yebeh.2024.109784_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107989","article-title":"Pediatric adverse reactions to antiseizure medications - An analysis of data from the Italian spontaneous reporting system (2001\u20132019)","volume":"119","author":"Franco","year":"2021","journal-title":"Epilepsy Behav."},{"issue":"12","key":"10.1016\/j.yebeh.2024.109784_b0120","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia."},{"issue":"7","key":"10.1016\/j.yebeh.2024.109784_b0125","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2012.01.019","article-title":"Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy","volume":"114","author":"Wang","year":"2012","journal-title":"Clin Neurol Neurosurg."},{"key":"10.1016\/j.yebeh.2024.109784_b0130","unstructured":"Rosenfeld W. CHAPTER 60 TOPIRAMATE. Wyllie E, editor: Wolters Kluwer; 2021. 708-14 p."},{"key":"10.1016\/j.yebeh.2024.109784_b0135","unstructured":"JM. S. CHAPTER 54 LAMOTRIGINE. 7th edition ed. Wyllie E, editor: Wolters Kluwer; 2021."},{"issue":"1","key":"10.1016\/j.yebeh.2024.109784_b0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14740338.2017.1248399","article-title":"Hyponatremia induced by antiepileptic drugs in patients with epilepsy","volume":"16","author":"Lu","year":"2017","journal-title":"Expert Opin Drug Saf."},{"issue":"4","key":"10.1016\/j.yebeh.2024.109784_b0145","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/14740338.2011.571201","article-title":"Drug safety evaluation of zonisamide for the treatment of epilepsy","volume":"10","author":"Zaccara","year":"2011","journal-title":"Expert Opin Drug Saf."},{"issue":"37","key":"10.1016\/j.yebeh.2024.109784_b0150","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.2174\/1381612823666170809115429","article-title":"Safety profile of the newest antiepileptic drugs: a curated literature review","volume":"23","author":"Palleria","year":"2017","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.yebeh.2024.109784_b0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure."},{"issue":"5","key":"10.1016\/j.yebeh.2024.109784_b0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-018-0523-7","article-title":"Lacosamide: A review in focal-onset seizures in patients with epilepsy","volume":"32","author":"Hoy","year":"2018","journal-title":"CNS Drugs."},{"key":"10.1016\/j.yebeh.2024.109784_b0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.seizure.2019.07.015","article-title":"Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature","volume":"71","author":"Mani","year":"2019","journal-title":"Seizure."},{"issue":"6","key":"10.1016\/j.yebeh.2024.109784_b0170","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jaip.2018.02.018","article-title":"The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study","volume":"6","author":"Guvenir","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"10","key":"10.1016\/j.yebeh.2024.109784_b0175","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14740338.2018.1518427","article-title":"Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy","volume":"17","author":"Moavero","year":"2018","journal-title":"Expert Opin Drug Saf."},{"issue":"4","key":"10.1016\/j.yebeh.2024.109784_b0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/cap.2010.0152","article-title":"Age-grouped differences in adverse drug events from psychotropic medication","volume":"21","author":"Safer","year":"2011","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"4","key":"10.1016\/j.yebeh.2024.109784_b0185","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3346\/jkms.2020.35.e17","article-title":"Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008\u20132017","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T23:15:05Z","timestamp":1714691705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"alternative-id":["S1525505024001653"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109784","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of adverse drug reactions associated with new antiseizure medications from the Korea Adverse Event Reporting System database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109784"}}